DB05747ExperimentalSmall molecule
R-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate the human body's immnune system to attack virus-infected cells and... It is expected to be topical treatment for cervical displasia and cervical high-risk human papillomavirus (HPV), the sexually transmitted virus that causes most cases of cervical cancer.
- Primary indication
- Investigated for use/treatment in cervical dysplasia/cancer and viral infection.Curator reviewed
Which companies are running trials of R-851, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account